|
|
||||||||||
|
J Am Coll Cardiol, 2007; 49:2408-2415, doi:10.1016/j.jacc.2007.02.058
(Published online 11 June 2007). © 2007 by the American College of Cardiology Foundation |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,#,*
,#
,#
,#
,#
* Institute for Clinical Evaluative Sciences
University Health Network
Sunnybrook and Women's Health Sciences Centre
Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Canada
|| London Health Sciences Centre, London, Canada
# University of Toronto, Toronto, Canada
Manuscript received November 9, 2006; revised manuscript received January 26, 2007, accepted February 27, 2007.
* Reprint requests and correspondence: Dr. Douglas S. Lee, Institute for Clinical Evaluative Sciences, Room G-106, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5 (Email: dlee{at}ices.on.ca).
Objectives: We sought to examine outcomes in recipients of implantable cardioverter-defibrillators (ICDs) and the effect of age, gender, and comorbidities on survival.
Background: Age, gender, and comorbidities may significantly affect outcomes in ICD recipients.
Methods: We examined factors associated with mortality in 2,467 ICD recipients in Ontario, Canada, using a province-wide database. Comorbidities were identified retrospectively by examining all diagnosis codes within the 3 years before implant.
Results: Mean ages at ICD implant were 63.2 ± 12.5 years (1,944 men) and 59.8 ± 15.9 years (523 women). Mortality rates at one and 2 years were 7.8% and 14.0%. Older age at implant increased the risk of death with hazard ratios (HR) of 2.05 (95% confidence interval [CI] 1.70 to 2.47) and 3.00 (95% CI 2.43 to 3.71) for those 65 to 74 years and
75 years, respectively (both p < 0.001), but gender was not a predictor of death. Common noncardiac conditions associated with death included peripheral vascular disease (adjusted HR 1.50, 95% CI 1.18 to 1.91), pulmonary disease (adjusted HR 1.35, 95% CI 1.10 to 1.66), and renal disease (adjusted HR 1.57, 95% CI 1.25 to 1.99). Many ICD recipients had prior heart failure (46.2%) with an increased HR of 2.33 for death (95% CI 1.96 to 2.76; p < 0.001). Greater comorbidity burden conferred increased risk, with HRs adjusted for age, gender, and heart failure of 1.72 (95% CI 1.44 to 2.05), 2.79 (95% CI 2.15 to 3.62), and 2.98 (95% CI 1.74 to 5.10) for those with 1, 2, and 3 or more noncardiac comorbidities, respectively (all p < 0.001).
Conclusions: Age, noncardiac comorbidities, and prior heart failure influence survival outcomes in ICD recipients. These factors should be considered in the care of ICD recipients.
| ||||||||||
Related Article
J. Am. Coll. Cardiol. 2007 49: 2416-2418.
This article has been cited by other articles:
![]() |
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons J. Am. Coll. Cardiol., May 27, 2008; 51(21): e1 - e62. [Full Text] [PDF] |
||||
![]() |
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons Circulation, May 27, 2008; 117(21): e350 - e408. [Full Text] [PDF] |
||||
![]() |
M. T. Koller, B. Schaer, M. Wolbers, C. Sticherling, H. C. Bucher, and S. Osswald Death Without Prior Appropriate Implantable Cardioverter-Defibrillator Therapy: A Competing Risk Study Circulation, April 15, 2008; 117(15): 1918 - 1926. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mittal Selecting Patients for an Implantable Cardioverter-Defibrillator: Can the Genie Be Put Back Into the Bottle? J. Am. Coll. Cardiol., January 22, 2008; 51(3): 297 - 299. [Full Text] [PDF] |
||||
![]() |
R. F. Redberg Disparities in Use of Implantable Cardioverter-Defibrillators: Moving Beyond Process Measures to Outcomes Data JAMA, October 3, 2007; 298(13): 1564 - 1566. [Full Text] [PDF] |
||||
![]() |
S. S. Chugh, K. Reinier, and E. C. Stecker Learning From a Real-World Analysis of Implantable Cardioverter-Defibrillator Recipients: Comorbidities Matter J. Am. Coll. Cardiol., June 26, 2007; 49(25): 2416 - 2418. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |